Reid Hoffman on the State of AI: xAI, SpaceX, and the Anthropic Regulatory Crisis

Reid Hoffman on the State of AI: xAI, SpaceX, and the Anthropic Regulatory Crisis

Reid Hoffman Critiques xAI and SpaceX AI Strategies

Reid Hoffman, co-founder of LinkedIn and investor in OpenAI and Anthropic, characterizes xAI as a "complete train wreck" and asserts that SpaceX is not an AI company. Hoffman argues that SpaceX is attempting to "buy its way into relevance" through acquisitions rather than developing organic AI capabilities.

xAI's Operational Instability

Hoffman's assessment of xAI is grounded in the company's leadership instability. By May 2026, all 11 of xAI's original co-founders had departed the company. This exodus, which began in February 2026 with the resignation of operationally central co-founder Tony Wu, has led to the company undergoing its "third restart." Additionally, Hoffman notes that xAI's Grok models have consistently lagged behind competitors from OpenAI and Anthropic in benchmark performance.

SpaceX's "Roll-up" Strategy

Following SpaceX's IPO on June 12, 2026, the company acquired the AI coding tool Cursor. Hoffman views this acquisition not as a sign of strength, but as evidence of a lack of internal capability, comparing SpaceX's approach to the "roll-up" strategy of the IAC conglomerate.

Furthermore, Hoffman dismisses SpaceX's claims of AI credentials based on its compute leasing business. While SpaceX leases AI infrastructure to companies like Anthropic, Hoffman describes this as being a "premium-priced CoreWeave," asserting that providing infrastructure does not make a company an AI company.

Regulatory Risks and the Anthropic Model Suspension

Unpredictable government intervention poses a significant risk to AI companies, as evidenced by the U.S. government's June 11, 2026, export control order forcing Anthropic to pull its Fable and Mythos models from the market.

The Fable and Mythos Incident

The suspension of foreign national access to these models was triggered by Amazon CEO Andy Jassy reporting a jailbreak in the Fable 5 model. Although Anthropic was already working to address the vulnerability and had flagged security concerns, the government's response was described by Hoffman as "autocratic willy-nilly" and lacking a principled rule of law.

Asymmetric Enforcement

Hoffman expressed particular concern over the asymmetry of the government's actions, noting that Anthropic was penalized while OpenAI was not. He warns that such unpredictable regulatory behavior creates a new category of investor risk for AI companies preparing for IPOs.

The Competitive Landscape: OpenAI vs. Anthropic

Contrary to the narrative of a zero-sum "cage match," Hoffman argues there is ample room for both OpenAI and Anthropic to succeed by occupying distinct competitive lanes.

  • Anthropic: Positioned as a leader in code, with expansion into design and legal sectors.
  • OpenAI: Functioning primarily as a consumer search front-end, with a strong but under-discussed Codex coding product.

Regarding the AI coding market, Hoffman suggests that Cursor—recently acquired by SpaceX—may have already peaked, facing mounting pressure from Claude Code and Codex since early 2026.

AI's Impact on the Workforce and Gen Z

Despite data showing that AI is displacing thousands of U.S. jobs per month—with graduate unemployment rising from 3.6% in 2019 to 5.6% in 2026—Hoffman argues that the entry-level job slump is misattributed to AI.

The "Agency Mindset"

Hoffman attributes the current employment struggles of Gen Z to global turbulence, pandemic-era over-hiring, and the difficulties of implementing remote work. He encourages graduates to adopt an "agency mindset," treating AI as a tool and companion rather than a threat. He suggests that Gen Z can differentiate themselves by becoming "AI native," helping organizations transition into AI-driven entities.

Future Ventures: Manas AI and Drug Discovery

Following his departure from the Microsoft board, Hoffman is focusing on Manas AI, a venture aimed at AI-driven drug discovery. The company focuses on generating small molecule proposals, which Hoffman describes as an "AI drug discovery factory for creating monopolies," leveraging the pharmaceutical industry's existing IP framework to establish market dominance.

Sources